Interim data from a phase 1 study from Intellia Therapeutics and Regeneron Pharmaceuticals is the first to support in vivo CRISPR genome editing in humans.
Peripheral Nerve Society (PNS)
Advertisement
Advertisement
Advertisement
Trending on CGTlive®
1
Nanoscope Nabs RMAT Designation for Retinitis Pigmentosa Gene Therapy MCO-010
2
Around the Helix: Cell and Gene Therapy Company Updates – September 3, 2025
3
Robert Alexander Wesselhoeft, PhD, on the Therapeutic Potential of Circular RNA
4
Preclinical Evidence for PH1 Gene Therapy
5
